Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled...

Area of Science:

• Gastroenterology
• Clinical Pharmacology
• Inflammatory Bowel Disease Research

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
• Patients with mild to moderate UC often require additional therapies when mesalamine is insufficient.
• Phosphatidylcholine (PC) has shown potential in previous trials for UC treatment.

Purpose of the Study:

• To assess the efficacy of LT-02, a modified-release phosphatidylcholine (PC) formulation, for inducing and maintaining remission in mild to moderate UC patients.
• To evaluate LT-02 in patients with an inadequate response to standard mesalamine treatment.

Main Methods:

• A multicenter, double-blind, randomized, placebo-controlled trial was conducted, including a 12-week induction phase (PCG-2) and a 48-week maintenance phase (PCG-4).
• Patients received LT-02 (0.8g QID or 1.6g BID) or placebo, alongside oral mesalamine (≥2.4 g/day).
• Primary endpoints were deep remission at week 12 (induction) and remission at week 48 (maintenance).

Main Results:

• The induction study (PCG-2) was halted early due to futility; no significant difference in deep remission was observed between LT-02 and placebo at week 12.
• In the maintenance trial (PCG-4), remission rates at week 48 were not significantly different between LT-02 BID (49.3%), mesalamine (50.0%), and placebo (43.2%).
• LT-02 demonstrated a favorable safety profile and was well-tolerated by patients.

Conclusions:

• LT-02 failed to demonstrate efficacy for induction of remission in mild to moderate UC patients inadequately responding to mesalamine.
• Preliminary signals of efficacy in maintenance therapy warrant further investigation in adequately powered studies.
• LT-02 is a safe and well-tolerated treatment option for UC.